Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00000815 | A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group | PHASE2 | COMPLETED | 270 | — | — | - | Aug 1, 2001 | Oct 28, 2021 | 46 | United States, Puerto Rico |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Participants who receive vaccination at 6 and 12 months of age |
| 2 | EXPERIMENTAL | Participants who receive vaccination only at 12 months of age |
| Name | Type | Description |
|---|---|---|
| Attenuvax | BIOLOGICAL | Measles virus vaccine (attenuate)administered subcutaneously at a single dose of 0.5 mL at 6 months of age |
| M-M-R-II | BIOLOGICAL | Measles-Mumps-Rubella vaccine (attenuated)administered subcutaneously as a single dose of 0.5 mL at 12 months of age |
Inclusion Criteria Patients must have: * Willing to have and receive results of HIV test * Been born to mothers with HIV infection or history of AIDS-defining condition by CDC criteria. * No history of opportunistic infection. * No known exposure to measles within 14 days prior to study entry. * C...